Q-omics provides the consensus-scored HNF1A profile across patient tissues and cancer cell-line models. HNF1A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HNF1A is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, HNF1A RNA expression shows 16,517 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, and TGCT as cancer lineages where HNF1A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNF1A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNF1A survival associations across molecular data types. HNF1A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNF1A RNA expression–survival associations across cancer types. High HNF1A expression shows unfavorable associations in MESO, ACC and LGG, but favorable associations in KIRC, SCLC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HNF1A RNA expression.
This table summarizes HNF1A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for HNF1A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNF1A shows lower tumor expression in KICH and higher tumor expression in KIRC, STAD, COAD, LIHC and LUAD. The KIRC box plot shows higher HNF1A RNA expression in tumor versus normal tissue (log2 FC = +1.166, t-test p < 0.001).
This table shows molecular features associated with HNF1A in patient tissues and cancer cell lines. In patient samples, HNF1A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, HNF1A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LIVER.
